前列腺癌（PCa）是巴西和全球男性中第二常见的恶性肿瘤。虽然正电子发射断层扫描（PET）前列腺特异性膜抗原（PSMA）已经使用了10多年，许多关于其在PCa初期分期和其他情况下表现优异的研究已经发表，但治疗决策常常仍基于常规影像信息。我们对35例PCa患者进行了回顾性分析，包括常规检查和PET PSMA。我们的研究结果显示，在分期分类和治疗选择方面发生了变化。PET PSMA是可靠的影像检查，已经在评估PCa患者的初期分期和生化复发以及其他潜在角色方面证明了其价值和优越性。需要进行前瞻性研究以评估以PSMA为指导的患者的结果。©2023年。外科肿瘤学会。

Prostate cancer (PCa) is the second most common malignant tumor in men in Brazil and worldwide. Although positron emission tomography (PET) prostate-specific membrane antigen (PSMA) has been used for over 10 years and several studies have been published regarding its superior performance in PCa primary staging and other scenarios, the management decision is often still based on conventional imaging information. A retrospective analysis was performed in 35 patients with PCa in the primary staging scenario with conventional exams as well as with PET PSMA. The findings of our study showed changes on the staging classification and significant impact on the therapeutic choice. PET PSMA is a dependable imaging exam and has already proved its worth and superiority when compared with conventional methods to evaluate PCa patients in primary staging and biochemical relapse, in addition to other potential roles. Prospective studies are needed to assess the outcome of patients whose management was guided by PSMA.© 2023. Society of Surgical Oncology.